Adoptive immunotherapy post bone-marrow transplantation

Blood Reviews

Volumn 10, Issue 4, 1996, Pages 237-241

  Perry, A R ^a   Mackinnon, S ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ALLOGENIC BONE MARROW TRANSPLANTATION; CONFERENCE PAPER; GRAFT VERSUS HOST REACTION; HUMAN; LEUKOCYTE TRANSFUSION; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0030482344     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(96)90007-7     Document Type: Conference Paper

References (24)

1. Barnes DWH, Corp MJ, Loutit JL et al. Treatment of murine leukaemias with x-rays and homologous bone marrow. BMJ 1956; 2: 627.
2. Barnes DWH, Loutit JL. Treatment of murine leukaemias with x-rays and homologous bone marrow. II. Br J Haem 1957; 3: 241.
3. Gale RP, Champlin RE. How does bone marrow transplantation cure leukaemia? Lancet 1984; 2: 28.
4. Weiden PL, Sullivan K, Flournoy N, Storb R, Thomas ED. The Seattle Marrow Transplant Team. Antileukaemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529.
5. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukaemia reactions after bone marrow transplantation. Blood 1990; 75: 555.
6. Kolb HJ, Mittermuller J, Clemm C et al. Donor leucocyte transfusions for treatment of recurrent chronic myelogenous leukaemia in marrow transplant patients. Blood 1990; 76: 246.
7. Antin JH. Graft-versus-leukaemia: no longer an epiphenomenon. Blood 1993; 82: 2273.
8. O'Reilly RJ, Mackinnon S, Kwak LW, Riddell SR. Allogeneic marrow transplants as adoptive immunotherapy: molecular and cellular interactions contributing to transferable leukaemia resistance and viral immunity. I. Donor leucocyte infusions for relapsed leukaemia after allogeneic BMT. Hematology 1995: Education Programme; American Society Of Haematology, p 101.
9. Van der Harst D, Goulmy E, Falkenburg JHF et al. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood 1994; 83: 1060-1066.
10. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukaemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041.
11. Mackinnon S, Papadopalous EB, Carabasi MH et al. Adoptive immunotherapy evaluating escalating doses of donor leucocytes for relapse of chronic myeloid leukaemia after bone marrow transplantation: separation of graft-versus-leukaemia responses from graft-versus-host disease. Blood 1995; 86: 1261-1268.
12. Kernan NA, Collins NH, Juliano L, Cartagena T, Dupont B, O'Reilly RJ. Clonable T lymphocytes in T-cell depleted bone marrow correlate with development of graft versus host disease. Blood 1986; 68: 770.
13. Mackinnon S, Barnett L, Heller G, O'Reilly RJ. Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukaemia. Blood 1994; 83: 3409.
14. Falkenburg JHF, Goselink HM, Van der Harst D et al. Growth inhibition of clonogenic leukaemic precursor cells by minor histocompatibility antigen-specific cytotoxic T-lymphocytes. J Exp Med 1991; 174: 27-33.
15. Slavin S, Ackerstein A, Naperstek E, Or R, Weiss L. The graft-versus-leukaemia phenomenon: is GVL separable from GVHD? Bone Marrow Transplant 1990; 6: 155.
16. Korngold R, Sprent J. T-cell subsets and graft-versus-host disease. Transplantation 1987; 44: 335.
17. Nimmer S, Giorgi J, Gajewski J et al. Selective depletion of CD8-positive cells for prevention of graft-versus-host disease following bone marrow transplantation: a randomised controlled trial. Transplantation 1994; 57: 82.
18. Giralt S, Hester J, Hirsch-Ginsberg C et al. CD-8 depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukaemia after allogeneic bone marrow transplantation. Blood 1995; 86: 4337.
19. Sosman JA, Oettal KR, Smith SD, Hank JA, Fisch P, Sondel PM. Specific recognition of human leukaemic cells by allogeneic cells. II. Evidence for HLA-D restricted determinants on leukaemic cells that are cross-reactive with determinants present on unrelated nonleukaemic cells. Blood 1990; 75: 2005.
20. Chen W, Pearce DJ, Rovira K, You SG, Cheever MA. T-cell immunity to the joining region of p210 bcr-abl protein. Proc Natl Acad Sci USA 1992; 89: 1468.
21. O'Reilly RJ, Mackinnon S, Kwak LW, Riddell SR. Allogeneic marrow transplants as adoptive immunotherapy: molecular and cellular interactions contributing to transferable leukaemia resistance and viral immunity. IL Tumor antigen-specific immunisation of allogeneic marrow transplant donors: the myeloma model. Haematology 1995: Education Program; American Society Of Haematology, p 101.
22. Soiffer RJ, Murray C, Cochran K et al. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell depleted allogeneic bone marrow transplantation. Blood 1992; 79: 517.
23. Weiss L, Reich S, Slavin S, Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant haematological disorders. 1. Treatment of murine leukaemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated immunotherapy. Cancer Invest 1992; 10: 19.
24. Slavin S, Naperstek E, Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukaemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195-2204.